Suppr超能文献

采用酶联免疫吸附测定法、重组免疫印迹法和聚合酶链反应检测中国献血者中的丙型肝炎病毒抗体及丙型肝炎病毒核糖核酸

Antibodies to hepatitis C virus and hepatitis C virus RNA in Chinese blood donors determined by ELISA, recombinant immunoblot assay and polymerase chain reaction.

作者信息

Zhang Y Y, Guo L S, Hao L J, Hansson B G, Widell A, Nordenfelt E

机构信息

Clinical Immunology Research Unit, Tongji Hospital, Tongji Medical University, Wuhan.

出版信息

Chin Med J (Engl). 1993 Mar;106(3):171-4.

PMID:7686839
Abstract

Antibodies to hepatitis C virus (anti-HCV) were determined in Chinese blood donors from the city of Wuhan by ELISA screening tests and confirmatory recombinant immunoblot assay (RIBA). 281 and 222 sera were sampled under similar conditions in 1989 and 1990, respectively. The first collection of sera was sent to Sweden in lyophilized form, the second directly as fresh, unfrozen sera. A high proportion (22%) of the lyophilized sera were positive in the screening assay but only 6 (2.10%) were positive by RIBA with antibodies against both the C100-3 and 5-1-1 peptides. HCV RNA could be detected by polymerase chain reaction (PCR) analysis in 3 of the 6 sera and in one reacting with C100-3 only. In the second material of fresh sera only 3 were positive in the screening anti-HCV ELISA, but none was RIBA or PCR positive. Thus, the overall prevalence of anti-HCV among the 503 Chinese blood donors as identified by RIBA was 1.2%, and that of HCV RNA by PCR was 0.8%. The confirmed antibody prevalence is higher than that reported in the western literature.

摘要

通过酶联免疫吸附试验(ELISA)筛查和确证性重组免疫印迹试验(RIBA),对来自武汉市的中国献血者进行丙型肝炎病毒抗体(抗-HCV)检测。分别于1989年和1990年在相似条件下采集了281份和222份血清样本。第一批血清样本以冻干形式送往瑞典,第二批则直接作为新鲜、未冷冻的血清送检。在筛查试验中,高比例(22%)的冻干血清呈阳性,但通过RIBA检测,只有6份(2.10%)同时针对C100-3和5-1-1肽段的抗体呈阳性。在这6份血清中的3份以及仅与C100-3反应的1份血清中,通过聚合酶链反应(PCR)分析可检测到HCV RNA。在第二批新鲜血清样本中,只有3份在抗-HCV ELISA筛查中呈阳性,但RIBA或PCR检测均为阴性。因此,通过RIBA确定的503名中国献血者中抗-HCV的总体流行率为1.2%,通过PCR检测的HCV RNA流行率为0.8%。经确证的抗体流行率高于西方文献报道的水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验